Amanote Research
Register
Sign In
Gemtuzumab Ozogamicin Makes a Comeback
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2017-132
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
September 20, 2017
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Antibody-Based Therapy of Acute Myeloid Leukemia With Gemtuzumab Ozogamicin
Frontiers in Bioscience - Landmark
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
Reinduction Chemotherapy With Gemtuzumab Ozogamicin and Intermediate/High-Dose Cytarabine: A Single-Center Experience
Open Journal of Blood Diseases
Coding Polymorphisms in CD33 and Response to Gemtuzumab Ozogamicin in Pediatric Patients With AML: A Pilot Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia
Oncologist
Cancer Research
Medicine
Oncology
Pretreatment of Leukemic Cells With Low-Dose Decitabine Markedly Enhances the Cytotoxicity of Gemtuzumab Ozogamicin
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report From the Children's Oncology Group
Clinical Cancer Research
Cancer Research
Oncology
Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Patients With Prior Gemtuzumab Ozogamicin: Literature Analysis of Survival After Defibrotide Treatment
Blood Cancer Journal
Oncology
Hematology
Gemtuzumab Ozogamicin in Children With Relapsed or Refractory Acute Myeloid Leukemia: A Report of Berlin-Frankfurt-Münster Study Group
Haematologica
Hematology
High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
Leukemia Research
Cancer Research
Oncology
Hematology
